AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9272782 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamylal test
Number of subjects: 39
Study 9272782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine test
Number of subjects: 39
Study 9272782 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic motor cortex stimulation therapy
Number of subjects: 39
Study 7881144 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of bupivacaine during both S1 and S2 (Group C)
Number of subjects: 42
Study 7881144 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of saline during S1 and S2 (Group A)
Number of subjects: 42
Study 7881144 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of saline during S1 and 20 mL of bupivacaine during S2 (Group B)
Number of subjects: 42
Study 2816636 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 300 (nonionic, iohexol)
Number of subjects: 40
Study 2816636 — intervention group
Group type: COMPARATOR
Intervention: Hypaque 60 (ionic, diatrizoate meglumine)
Number of subjects: 40
Study 776464 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 31353275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with CT-DM framework
Number of subjects: 431
Study 31353275 — intervention group
Group type: COMPARATOR
Intervention: Control group without CT-DM framework
Number of subjects: 431
Study 31443731 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 734
Study 31443731 — intervention group
Group type: COMPARATOR
Intervention: Regional lymphadenectomy
Number of subjects: 734
Study 28219132 — intervention group
Group type: EXPERIMENTAL
Intervention: Artery approach method
Number of subjects: 60
Study 28219132 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (Control)
Number of subjects: 60
Study 26068297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent PTH administration (iPTH)
Number of subjects: 82
Study 26068297 — intervention group
Group type: COMPARATOR
Intervention: Chronic PTH hypersecretion in primary hyperparathyroidism (PHP)
Number of subjects: 82
Study 26068297 — intervention group
Group type: COMPARATOR
Intervention: Surgical restoration of normal parathyroid function
Number of subjects: 82
Study 23587982 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 25 mg/day (initial dose), titrated to a maximum of 100 mg/day based on clinical response
Number of subjects: 304
Study 23587982 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (various doses)
Number of subjects: 304
Study 21693027 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted Problem Solving Therapy (C-MAP), 8 sessions lasting approximately 50 minutes each over 3 months
Number of subjects: 0
Study 21693027 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 20015817 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the transurethral catheter on the first postoperative day (Group 1)
Number of subjects: 78
Study 20015817 — intervention group
Group type: COMPARATOR
Intervention: Removal of the catheter after discontinuation of PCEA (Group 2)
Number of subjects: 78
Study 22054688 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Conservation System (BCS)
Number of subjects: 216
Study 22054688 — intervention group
Group type: COMPARATOR
Intervention: 3-way stopcock
Number of subjects: 216
Study 16230866 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP-guided up-titration of beta blocker
Number of subjects: 41
Study 16230866 — intervention group
Group type: COMPARATOR
Intervention: Standard care (clinical group)
Number of subjects: 41
Study 16230866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BNP and standard care)
Number of subjects: 41
Study 16230866 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP group
Number of subjects: 41
Study 12746760 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Pioglitazone once daily
Number of subjects: 60
Study 12746760 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 60
Study 10228112 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II polymorphism (specifically DR4 and DR7 alleles)
Number of subjects: 98
Study 10228112 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II polymorphism (specifically DR7 allele)
Number of subjects: 98
Study 10228112 — intervention group
Group type: COMPARATOR
Intervention: Control group (39 subjects without atopy)
Number of subjects: 98
Study 7503047 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of vitamin C and beta-carotene (mean intakes: 138 mg/day vitamin C, 5.3 mg/day beta-carotene)
Number of subjects: 1556
Study 2141231 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mechanics instruction (one classroom session and two on-site sessions)
Number of subjects: 30
Study 2141231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no body mechanics instruction)
Number of subjects: 30
Study 108187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 40
Study 108187 — intervention group
Group type: COMPARATOR
Intervention: Membrane oxygenator
Number of subjects: 40
Study 11598528 — intervention group
Group type: EXPERIMENTAL
Intervention: Levator anus massage
Number of subjects: 0
Study 11598528 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 0
Study 11598528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild levator stretch
Number of subjects: 0
Study 11598528 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31196835 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 18
Study 31196835 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study 30328176 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.3% triclosan + 2.0% PVM/MA copolymer + 1,450 ppm fluoride (test)
Number of subjects: 102
Study 30328176 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste containing 1,450 ppm fluoride (control)
Number of subjects: 102
Study 26745832 — intervention group
Group type: EXPERIMENTAL
Intervention: Active balance-point training
Number of subjects: 63
Study 26745832 — intervention group
Group type: COMPARATOR
Intervention: Sham balance-point training
Number of subjects: 63
Study 24074457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal inhalation of 24 IU of oxytocin
Number of subjects: 20
Study 24074457 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 20
Study 22618520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine with Lipiodol emulsion
Number of subjects: 101
Study 22618520 — intervention group
Group type: COMPARATOR
Intervention: Control group (without nitroglycerine)
Number of subjects: 101
Study 20197785 — intervention group
Group type: EXPERIMENTAL
Intervention: A. bisporus alpha‐glucans (5 g glucans/day)
Number of subjects: 56
Study 20197785 — intervention group
Group type: COMPARATOR
Intervention: Control fruit juice (200 ml/day)
Number of subjects: 56
Study 17628352 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine (0.5 mg/day)
Number of subjects: 119
Study 17628352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 16376736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' preferences for desired experiences during the last week of life
Number of subjects: 92
Study 16376736 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations about treatment preferences
Number of subjects: 92
Study 16376736 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogates' understanding of patients' preferences
Number of subjects: 92
Study 12408201 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored self-help nutrition and PA intervention (TX1)
Number of subjects: 0
Study 12408201 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored self-help nutrition and PA intervention plus four telephone counseling calls based on MI (TX2)
Number of subjects: 0
Study 12408201 — intervention group
Group type: COMPARATOR
Intervention: Standard (existing commercial) nutrition and PA intervention materials (Group 1)
Number of subjects: 0
Study 10205584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime uncooked cornstarch (0.3 g kg‐1 body weight)
Number of subjects: 12
Study 10205584 — intervention group
Group type: COMPARATOR
Intervention: Conventional snack (wholemeal bread, 0.6 g of carbohydrates kg‐1 body weight)
Number of subjects: 12
Study 10205584 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-free placebo
Number of subjects: 12
Study 7842183 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (80:20 helium:oxygen) for 15 min
Number of subjects: 27
Study 7842183 — intervention group
Group type: COMPARATOR
Intervention: Room air for 15 min (control)
Number of subjects: 27
Study 2222979 — intervention group
Group type: EXPERIMENTAL
Intervention: Instromedix Baro-Graf QD home blood pressure monitor
Number of subjects: 40
Study 417644 — intervention group
Group type: EXPERIMENTAL
Intervention: L-amino acid solutions (0.24 g N/kg body weight/day) + glucose and fructose
Number of subjects: 2
Study 417644 — intervention group
Group type: EXPERIMENTAL
Intervention: L-amino acid solutions (0.24 g N/kg body weight/day) + glucose, fructose, and fat emulsions (30-40% of total calories, 30 kcal/kg body weight/day)
Number of subjects: 2
Study 417644 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 31876947 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy for chronic pain
Number of subjects: 0
Study 31876947 — intervention group
Group type: EXPERIMENTAL
Intervention: Group chronic pain self-management
Number of subjects: 0
Study 31876947 — intervention group
Group type: COMPARATOR
Intervention: Usual care (taper only)
Number of subjects: 0
Study 30828718 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of RNase T
Number of subjects: 0
Study 30828718 — intervention group
Group type: EXPERIMENTAL
Intervention: CCA-adding enzyme
Number of subjects: 0
Study 30828718 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered catalytic efficiency and temperature sensitivity
Number of subjects: 0
Study 30828718 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional enzyme variants
Number of subjects: 0
Study 27324506 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan) 20-600 mg
Number of subjects: 50
Study 27324506 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan) 200 mg with food
Number of subjects: 50
Study 27324506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26688235 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (3.5 g/m²) with temozolomide (150 mg/m²)
Number of subjects: 98
Study 26688235 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (3.5 g/m²), procarbazine (100 mg/m²), vincristine (1.4 mg/m²), and cytarabine (3 mg/m²)
Number of subjects: 98
Study 23421759 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily for 12 months)
Number of subjects: 200
Study 23421759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose monohydrate and stearic acid, same weight as zinc capsules)
Number of subjects: 200
Study 21424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 60
Study 21424975 — intervention group
Group type: COMPARATOR
Intervention: Normobaric oxygen therapy
Number of subjects: 60
Study 21424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial complex IV (mtCIV) activity
Number of subjects: 60
Study 21424975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative stress (lipid peroxidation)
Number of subjects: 60
Study 19429632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital fibrinolysis (rt-PA)
Number of subjects: 840
Study 19429632 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty
Number of subjects: 840
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-uninfected women
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic site (Blantyre)
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic site (Lilongwe)
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic site (Lusaka)
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection status
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 20 to 24 years
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status (divorced, widowed, or separated)
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital ulcer treatment in the last year
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stillbirth
Number of subjects: 2636
Study 16601659 — intervention group
Group type: EXPERIMENTAL
Intervention: History of preterm delivery
Number of subjects: 2636
Study 14578918 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 120
Study 14578918 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 120
Study 14578918 — intervention group
Group type: COMPARATOR
Intervention: Comparison between losartan and atenolol
Number of subjects: 120
Study 10391568 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention group (sent correspondence, print material, and telephone contacts tailored to each recipient)
Number of subjects: 548
Study 10391568 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention group (mailed a letter and reminder to invite to urology clinic)
Number of subjects: 548
Study 8536887 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg daily
Number of subjects: 105
Study 8536887 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg daily
Number of subjects: 105
Study 8536887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 1910096 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (bicarbonate loading)
Number of subjects: 8
Study 1910096 — intervention group
Group type: COMPARATOR
Intervention: Control (CaCO3)
Number of subjects: 8
Study 6749426 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1012
Study 6749426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012
Study 6749426 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who dropped out
Number of subjects: 1012
Study 30475006 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention for alcohol use
Number of subjects: 35
Study 28294985 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus rhamnosus CGMCC1.3724)
Number of subjects: 105
Study 25085275 — intervention group
Group type: EXPERIMENTAL
Intervention: GS 500 mg/CS 400 mg three times daily capsules (GI)
Number of subjects: 1120
Study 25085275 — intervention group
Group type: EXPERIMENTAL
Intervention: GS 500 mg/CS 400 mg once daily sachet (GII)
Number of subjects: 1120
Study 25085275 — intervention group
Group type: COMPARATOR
Intervention: GH 500 mg/CS 400 mg three times daily (GIII)
Number of subjects: 1120
Study 23588112 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth-arrested neonatal dermal fibroblasts and keratinocytes delivered via pump spray in a fibrin sealant-based matrix, plus a foam dressing and four-layer compression bandaging for 12 weeks or until healed.
Number of subjects: 228
Study 23588112 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (no active treatment).
Number of subjects: 228
Study 21915478 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine replacement
Number of subjects: 32
Study 21915478 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study 19506099 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123
Number of subjects: 22
Study 19506099 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg)
Number of subjects: 22
Study 17029610 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (100 microg weekly for 52 weeks)
Number of subjects: 76
Study 12772754 — intervention group
Group type: EXPERIMENTAL
Intervention: Menicon Z RGP lenses worn continuously for 30 days (29 nights)
Number of subjects: 0
Study 12772754 — intervention group
Group type: COMPARATOR
Intervention: Acuvue hydrogel lenses worn for 7 days (6 nights)
Number of subjects: 0
Study 11194701 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based smoking control program
Number of subjects: 65
Study 11194701 — intervention group
Group type: COMPARATOR
Intervention: General health education control condition
Number of subjects: 65
Study 9754162 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000‐centistoke silicone oil as the retinal tamponade
Number of subjects: 2439
Study 7546107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpolymer underpads
Number of subjects: 166
Study 7546107 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer underpads
Number of subjects: 166
Study 7546107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth underpads
Number of subjects: 166
Study 7546107 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaper products
Number of subjects: 166
Study 7546107 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 166
Study 3042637 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 223
Study 3042637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 30333014 — intervention group
Group type: EXPERIMENTAL
Intervention: YogaFit
Number of subjects: 40
Study 30333014 — intervention group
Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 40
Study 28238203 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐53718678 (single doses of 25-1000 mg)
Number of subjects: 9
Study 28238203 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐53718678 (multiple doses of 250 mg every 24 h, 500 mg q24h, 250 mg every 12 h for 8 days)
Number of subjects: 9
Study 28238203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 28238203 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐53718678
Number of subjects: 9
Study 26275644 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine prenatal care and music listening (experimental group)
Number of subjects: 296
Study 26275644 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care only (control group)
Number of subjects: 296
Study 24139587 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inserted foreign body (SIFB) group
Number of subjects: 45
Study 24139587 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 24139587 — intervention group
Group type: EXPERIMENTAL
Intervention: SIFB group
Number of subjects: 45
Study 20215977 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET) - conjugated equine estrogens 0.625 mg daily
Number of subjects: 200
Study 20215977 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen + progesterone therapy (EPT) - ET plus medroxyprogesterone acetate 2.5 mg daily
Number of subjects: 200
Study 20215977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18198066 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to personal antenatal health records (PI group)
Number of subjects: 193
Study 18198066 — intervention group
Group type: COMPARATOR
Intervention: Access to general pregnancy health information (GI group)
Number of subjects: 193
Study 16834970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruanjian Xiaoying Decoction (RJXYD) combined with levothyroxine
Number of subjects: 80
Study 16834970 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine and prednisone
Number of subjects: 80
Study 12076344 — intervention group
Group type: EXPERIMENTAL
Intervention: Active IFC
Number of subjects: 30
Study 12076344 — intervention group
Group type: COMPARATOR
Intervention: Sham IFC
Number of subjects: 30
Study 12076344 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 30
Study 10445673 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (18 or 36 microg/kg loading dose and 0.2 or 0.3 microg/kg/min infusion)
Number of subjects: 18
Study 10445673 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (high-dose)
Number of subjects: 18
Study 10445673 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (both doses)
Number of subjects: 18
Study 10445673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10445673 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 18
Study 7788690 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiktor stent
Number of subjects: 65
Study 7788690 — intervention group
Group type: COMPARATOR
Intervention: Palmaz-Schatz stent
Number of subjects: 65
Study 2229946 — intervention group
Group type: EXPERIMENTAL
Intervention: skills training plus incentive
Number of subjects: 60
Study 2229946 — intervention group
Group type: EXPERIMENTAL
Intervention: skills training only
Number of subjects: 60
Study 2229946 — intervention group
Group type: COMPARATOR
Intervention: placebo plus incentive
Number of subjects: 60
Study 2229946 — intervention group
Group type: COMPARATOR
Intervention: placebo without incentive
Number of subjects: 60
Study 2229946 — intervention group
Group type: EXPERIMENTAL
Intervention: skills training
Number of subjects: 60
Study 2229946 — intervention group
Group type: EXPERIMENTAL
Intervention: incentive
Number of subjects: 60
Study 316786 — intervention group
Group type: EXPERIMENTAL
Intervention: Portacaval shunt surgical treatment
Number of subjects: 80
Study 316786 — intervention group
Group type: COMPARATOR
Intervention: No surgical treatment (control)
Number of subjects: 80
Study 316786 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of large esophageal varices
Number of subjects: 80
Study 316786 — intervention group
Group type: EXPERIMENTAL
Intervention: Two episodes of gastrointestinal bleeding within one year
Number of subjects: 80